David Enloe is the President and CEO at Recro, a CDMO specializing in oral solid dose drugs.
David Enloe is the President and CEO at Recro, a CDMO specializing in oral solid dose drugs. The company expanded its operations by acquiring Irisys for nearly $50 million, aiming to become a full-service CDMO with bi-coastal manufacturing capabilities. This acquisition is part of Recro's strategy to strengthen leadership, diversify clients, fortify finances, and enhance capabilities.
Full founder directory · Investor directory · Company funding database · Fundraising library